BiotechTube

ceftazidim-avibactam (CAZ-AVI, experimental product) + meropenem (active comparator)

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Nosocomial Pneumonia (NP)

Conditions

Nosocomial Pneumonia (NP), Ventilator-associated Pneumonia (VAP)

Trial Timeline

Apr 1, 2013 → Jan 1, 2016

NCT ID
NCT01808092

About ceftazidim-avibactam (CAZ-AVI, experimental product) + meropenem (active comparator)

ceftazidim-avibactam (CAZ-AVI, experimental product) + meropenem (active comparator) is a phase 3 stage product being developed by Pfizer for Nosocomial Pneumonia (NP). The current trial status is completed. This product is registered under clinical trial identifier NCT01808092. Target conditions include Nosocomial Pneumonia (NP), Ventilator-associated Pneumonia (VAP).

What happened to similar drugs?

0 of 3 similar drugs in Nosocomial Pneumonia (NP) were approved

Approved (0) Terminated (1) Active (2)
🔄levofloxacin; imipenem/cilastitinJohnson & JohnsonPhase 3
❌vancomycin monotherapy + daptomycin monotherapyNovartisPhase 3
🔄linezolidPfizerPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01808092Phase 3Completed

Competing Products

7 competing products in Nosocomial Pneumonia (NP)

See all competitors
ProductCompanyStageHype Score
levofloxacin; imipenem/cilastitinJohnson & JohnsonPhase 3
40
Ceftazidime-avibactamAbbViePhase 1
21
Ceftolozane/TazobactamMerckPhase 1
29
vancomycin monotherapy + daptomycin monotherapyNovartisPhase 3
32
linezolidPfizerPhase 3
40
C Group + E GroupPfizerPhase 2/3
34
VeronateBristol Myers SquibbPre-clinical
26